Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Arcus Biosciences to Participate at Upcoming Virtual Investor Events By: Arcus Biosciences via Business Wire February 06, 2023 at 16:05 PM EST Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate at the following upcoming February 2023 virtual investor events: SVB Securities Virtual Global Biopharma Conference Date: Tuesday, February 14th, 2023 Time: 12:00 p.m. ET Format: Fireside Chat Citi’s 2023 Virtual Oncology Leadership Summit Date: Tuesday, February 21, 2023 Time: 1:00 p.m. ET Format: Fireside Chat Live webcasts of the fireside chats will be available by visiting the “Investors & Media” section of the Arcus Biosciences website at www.arcusbio.com. Replays of the webcast will be available following the live event. About Arcus Biosciences Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has advanced six investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and A2a/A2b receptors) and HIF-2a. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20230206005139/en/Contacts Investor Inquiries Pia Banerjee Head of Investor Relations & Strategy (617) 459-2006 pbanerjee@arcusbio.com Media Inquiries Holli Kolkey VP of Corporate Communications (650) 922-1269 hkolkey@arcusbio.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Arcus Biosciences to Participate at Upcoming Virtual Investor Events By: Arcus Biosciences via Business Wire February 06, 2023 at 16:05 PM EST Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate at the following upcoming February 2023 virtual investor events: SVB Securities Virtual Global Biopharma Conference Date: Tuesday, February 14th, 2023 Time: 12:00 p.m. ET Format: Fireside Chat Citi’s 2023 Virtual Oncology Leadership Summit Date: Tuesday, February 21, 2023 Time: 1:00 p.m. ET Format: Fireside Chat Live webcasts of the fireside chats will be available by visiting the “Investors & Media” section of the Arcus Biosciences website at www.arcusbio.com. Replays of the webcast will be available following the live event. About Arcus Biosciences Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has advanced six investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and A2a/A2b receptors) and HIF-2a. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20230206005139/en/Contacts Investor Inquiries Pia Banerjee Head of Investor Relations & Strategy (617) 459-2006 pbanerjee@arcusbio.com Media Inquiries Holli Kolkey VP of Corporate Communications (650) 922-1269 hkolkey@arcusbio.com
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate at the following upcoming February 2023 virtual investor events: SVB Securities Virtual Global Biopharma Conference Date: Tuesday, February 14th, 2023 Time: 12:00 p.m. ET Format: Fireside Chat Citi’s 2023 Virtual Oncology Leadership Summit Date: Tuesday, February 21, 2023 Time: 1:00 p.m. ET Format: Fireside Chat Live webcasts of the fireside chats will be available by visiting the “Investors & Media” section of the Arcus Biosciences website at www.arcusbio.com. Replays of the webcast will be available following the live event. About Arcus Biosciences Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has advanced six investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and A2a/A2b receptors) and HIF-2a. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20230206005139/en/
Investor Inquiries Pia Banerjee Head of Investor Relations & Strategy (617) 459-2006 pbanerjee@arcusbio.com Media Inquiries Holli Kolkey VP of Corporate Communications (650) 922-1269 hkolkey@arcusbio.com